About US
Contact us
-
After coming up short in COVID, Valneva focuses on chikungunya vaccine launchAfter striking out in an attempt to create a niche for its COVID-19 vaccine, Valneva is taking its swings at what it does best—developing, manufacturing and commercializing vaccines for a variety of2024/4/18
-
Vanda turns back on hostile takeover bid by CDMO Future PakTwo weeks after gaining a hard-earned FDA label expansion for its long-established antipsychotic drug Fanapt (iloperidone), Vanda Pharmaceuticals has derailed a hostile takeover bid. By employing a s2024/4/16
-
UPDATED: Novo Nordisk attracts lawmakers' scrutiny after dropping discounted insulin product LevemirNovo Nordisk is receiving pushback from a trio of lawmakers over its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year.2024/4/16
-
AbbVie touts Rinvoq win in giant cell arteritis, potentially teeing up another label expansionLess than a year ago, AbbVie's star immunology drug Rinvoqpicked up its seventh FDA approvalwhen the agency endorsed it in Crohn's disease. After a new positive pivotal trial, the drug could be bound2024/4/11
-
CDMO Fujifilm Diosynth's restructuring plan may leave up to 240 staffers out of workFujifilm Diosynth Biotechnologies'ventureinto separate small-scale and large-scale business units doesn't appear to be working out as planned. Tuesday, the CDMO revealed that it'sreworking its small-2024/4/11
-
Roche touts near-complete suppression of multiple sclerosis relapse for injectable OcrevusOne-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis (MS) drug Ocrevus ahead of an FDA decision, the Swiss pharma said. A subcutaneous fo2024/4/9
-
Eli Lilly, plaintiffs agree to scrap $13.5M insulin pricing settlementAlmost a year after originally proposing a $13.5 million settlement to end years of litigation relating to alleged insulin overpricing, Eli Lilly and plaintiffs in the nationwide class-action lawsuit2024/4/9
-
With Vyvgart 'firing' in myasthenia gravis, argenx lays launch plans for next potential autoimmune approval: CEODespite a pair of clinical misfires in 2023, argenx has stuck by the thesis that its star drug Vyvgart, also known as efgartigimod, can tackle a wide array of autoimmune diseases linked to immunoglob2024/4/2
-
Eli Lilly inks deal to acquire Nexus manufacturing plant in Wisconsin as Mounjaro and Zepbound shortages drag onAs doctors and patients in the U.S. grapple with widening shortages of the popular diabetes therapy Mounjaro and its obesity counterpart Zepbound, the maker of the tirzepatide drugs, Eli Lilly, is fo2024/4/2
-
Another delay for Abeona's topical gene therapy pz-cel as FDA sends out a rejectionDating to a 2019clinical holdof a phase 3 trial, getting its gene therapy rademagene zamikeracel (pz-cel) across the FDA finish line has been a challenge for troubled Abeona Therapeutics. Now the wai2024/3/28